Maternal obesity impairs specific regulatory pathways in human myometrial arteries.
Obese women (body mass index ≥30 kg/m(2)) are at greater risk than normal weight women of pregnancy complications associated with maternal and infant morbidity, particularly the development of cardiovascular disease and metabolic disorders in later life; why this occurs is unknown. Nonpregnant, obese individuals exhibit systemic vascular endothelial dysfunction. We tested the hypothesis that obese pregnant women have altered myometrial arterial function compared to pregnant women of normal (18-24 kg/m(2)) and overweight (25-29 kg/m(2)) body mass index. Responses to vasoconstrictors, U46619 (thromboxane mimetic) and arginine vasopressin, and vasodilators, bradykinin and the nitric oxide donor sodium nitroprusside, were assessed by wire myography in myometrial arteries from normal weight (n = 18), overweight (n = 18), and obese (n = 20) women with uncomplicated pregnancies. Thromboxane-prostanoid receptor expression was assessed using immunostaining in myometrial arteries of normal weight and obese women. Vasoconstriction and vasodilatation were impaired in myometrial arteries from obese women with otherwise uncomplicated pregnancies. Disparate agonist responses suggest that vascular function in obese women is not globally dysregulated but may be specific to thromboxane and nitric oxide pathways. Because obesity rates are escalating, it is important to identify the mechanisms underlying impaired vascular function and establish why some obese women compensate for vascular dysfunction and some do not. Future studies are needed to determine whether central adiposity results in an altered endocrine milieu that may promote vascular dysfunction by altering the function of perivascular adipose tissue.
Maternal and Fetal Health Research Centre, Institute of Human Development, Faculty of Medical and Human Sciences, The University of Manchester, Manchester, United Kingdom.
Christina E
CE
Hayward
Elizabeth J
EJ
Cowley
Tracey A
TA
Mills
Colin P
CP
Sibley
Mark
M
Wareing
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology; D001158:Arteries / Q000187:drug effects / Q000503:physiopathology*; D001706:Biopsy; D015992:Body Mass Index; D001835:Body Weight / Q000502:physiology; D004730:Endothelium, Vascular / Q000502:physiology; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D007213:Indomethacin / Q000494:pharmacology; D009215:Myometrium / Q000098:blood supply* / Q000187:drug effects; D009569:Nitric Oxide / Q000502:physiology; D009765:Obesity / Q000503:physiopathology*; D011225:Pre-Eclampsia / Q000503:physiopathology; D011247:Pregnancy; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology*; D013931:Thromboxanes / Q000502:physiology; D014661:Vasoconstriction / Q000502:physiology; D014664:Vasodilation / Q000502:physiology
D000894:Anti-Inflammatory Agents, Non-Steroidal; D013931:Thromboxanes; D009569:Nitric Oxide; D007213:Indomethacin
body mass index; myometrium; nitric oxide; preeclampsia; pregnancy; thromboxane; vascular